Sarepta Therapeutics Inc. (srpt 1.25 09/15/27)
13F holders, Q3 2025 (September 30)5holders −1
0new positions
1sold out
$0.88avg. 13F price*
At the end of Q3 2025, 5 institutions reported holding Sarepta Therapeutics Inc. (srpt 1.25 09/15/27) in their 13F filings, down 1 from Q2 2025. 0 opened new positions and 1 sold out. The largest holders were BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($3.8M), State of Wisconsin Investment Board ($2.6M) and Fort Baker Capital Management LP ($2.2M).
- Company
- Sarepta Therapeutics Inc. (srpt 1.25 09/15/27)
- CUSIP
- 803607AD2
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $3K |
All 13F filers, Q2 2025 → Q3 2025: 1,000,000 shares bought and 3,500 shares sold, net +996,500 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | No change | 4,400,000 | $3.8M |
| State of Wisconsin Investment Board | 0.01% | Add +50.0% | 3,000,000 | $2.6M |
| Fort Baker Capital Management LP | 0.37% | No change | 2,500,000 | $2.2M |
| Exome Asset Management LLC | 1.17% | No change | 2,000,000 | $1.8M |
| Rothschild Investment LLC | 0.00% | No change | 1,000 | $880 |
"% of holder's portfolio" is SAREPTA THERAPEUTICS INC (SRPT 1.25 09/15/27)'s weight in each manager's 13F, not the share of Sarepta Therapeutics Inc. (srpt 1.25 09/15/27) the manager owns.